Company: INMB
Filing Date: 2025-05-07
Form Type: 8-K
Source: 0001213900-25-040727
Chunk: 1

Company: Inmune Bio, Inc.
Filing Date: 2025-05-07
Form: 8-K
Item: Item 4.01
Chunk 1
---
 the fiscal year ending
December 31, 2025.

During the fiscal years ended December 31, 2024
and 2023 and through May 7, 2025, neither the Company nor anyone on its behalf consulted with CBIZ CPAs regarding (1) the application
of accounting principles to a specified transaction, completed or proposed, or the type of audit opinion that might be rendered on the
Company's financial statements, and neither a written report nor oral advice was provided to the Company that CBIZ CPAs concluded was
an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issue, or (2)
any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions)
or a reportable event (as described in Item 304(a)(1)(v) of Regulation S-K).

Item 9.01 Financial
Statements and Exhibits

(d) Exhibits

  Exhibit No.      Description of Exhibit                                                                                                                                                                    
         16.1      Letter from Marcum LLP dated May 7, 2025                                                                                                                                                  
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
          104      Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.  

SIGNATURES

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                         INMUNE BIO INC.                               
  Date: May 7, 2025      By:                  /s/ David Moss           
                                              David Moss               
                                              Chief Financial Officer